L. Pratiques-en-obstétrique-et-en-néonatologie-ont-Évolué, La survie des enfants nés avant terme s'est améliorée et ceux-ci sont donc plus nombreux

. Cependant, des prédispositions multigéniques ainsi que l'environnement respiratoire de l'enfant jouent un rôle essentiel

T. Feltes, Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease, J Pediatr, 2003.

M. Grimaldi, Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia, Pediatr Infect Dis J, 2004.

M. Grimaldi, B. Gouyon, P. Sagot, C. Quantin, F. Huet et al., Palivizumab efficacy in preterm infants with gestational age ???30 weeks without bronchopulmonary dysplasia, Pediatric Pulmonology, vol.90, issue.3, 2007.
DOI : 10.1002/ppul.20503

J. Gouyon, J. Rozé, C. Guillermet-fromentin, I. Glorieux, L. Adamon et al., Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study, Epidemiology and Infection, vol.31, issue.04, 2013.
DOI : 10.1067/mpd.2002.128114

URL : https://hal.archives-ouvertes.fr/hal-01194211

J. Hascoet, Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting. Arch Pédiatrie Organe Off Sociéte Fr Pédiatrie, 2008.

T. Andabaka, Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children, Cochrane Database Syst Rev, 2013.

S. , S. Française-de-néonatologie, H. Autorité-de-santé, and -. , SYNAGIS : recommandations SFN Juillet http://www.reseaupsof.fr/medias/recommandations_synagis, p.5014, 2007.

M. Frogel, A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis, Journal of Managed Care Pharmacy, vol.16, issue.1, 2010.
DOI : 10.18553/jmcp.2010.16.1.46

N. Homaira, Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective, International Journal of Pediatrics, vol.26, issue.6, 2014.
DOI : 10.1016/S0022-3476(88)80008-8

C. Parnes, Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry, Pediatr Pulmonol, 2003.

L. Bernard, Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants. Arch Pédiatrie Organe Off Sociéte Fr Pédiatrie, 2015.

J. Figueras-aloy, FLIP-2 Study, The Pediatric Infectious Disease Journal, vol.27, issue.9, 2008.
DOI : 10.1097/INF.0b013e3181710990

X. Carbonell-estrany, Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32???35 weeks??? gestational age with more informed use of risk factors?, The Journal of Maternal-Fetal & Neonatal Medicine, vol.3, issue.10, 2015.
DOI : 10.1136/thoraxjnl-2011-201054c.170

E. Simões, European risk factors' model to predict hospitalization of premature infants born 33???35 weeks' gestational age with respiratory syncytial virus: validation with Italian data, The Journal of Maternal-Fetal & Neonatal Medicine, vol.35, issue.1, 2011.
DOI : 10.1542/peds.102.3.531

S. Yoshihara, Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics, 2013.

D. Prais, Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely, Chest, vol.149, issue.3, p.2015
DOI : 10.1378/chest.15-0328

D. Parlement and E. Et, relatif aux médicaments à usage pédiatrique, modifiant le règlement (CEE) no 1768, CE ainsi que le règlement (CE) no 726, 1901.

K. Robinson, O. Odelola, and I. Saldanha, Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis, Cochrane Database Syst Rev, 2014.

D. Pinquier, Palivizumab immunoprophylaxis: use in clinical practice, safety and beneficial effects in France. Arch Pédiatrie Organe Off Sociéte Fr Pédiatrie, 2009.

M. Blanken, Respiratory syncytial virus and recurrent wheeze, N Engl J Med, 2013.

-. , L. Bains, and H. Savoie, Rhône Alpes -Dieppe

. Cholet, . Maine, and . Loire, Ile de France. -CH Lariboisière Paris Ile de France. -Blanc mesnil, Seine Saint Denis